✦ LIBER ✦

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

✍ Scribed by von Minckwitz, Gunter; Schneeweiss, Andreas; Loibl, Sibylle; Salat, Christoph; Denkert, Carsten; Rezai, Mahdi; Blohmer, Jens U; Jackisch, Christian; Paepke, Stefan; Gerber, Bernd; Zahm, Dirk M; Kümmel, Sherko; Eidtmann, Holger; Klare, Peter; Huober, Jens; Costa, Serban; Tesch, Hans; Hanusch, Claus; Hilfrich, Jörn; Khandan, Fariba; Fasching, Peter A; Sinn, Bruno V; Engels, Knut; Mehta, Keyur; Nekljudova, Valentina; Untch, Michael

Book ID: 122656694
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 459 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70160-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of everolimus and carbopla

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

✍ Singh, Jasmeet; Novik, Yelena; Stein, Stacey; Volm, Matthew; Meyers, Marlene; Sm 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 239 KB

Neoadjuvant and adjuvant trastuzumab in

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Gianni, Luca; Eiermann, Wolfgang; Semiglazov, Vladimir; Lluch, Ana; Tjulandin, S 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 294 KB

Neoadjuvant chemotherapy with trastuzuma

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 124 KB

Efficacy and safety of neoadjuvant pertu

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; M 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 217 KB

6 months versus 12 months of adjuvant tr

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

✍ Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 358 KB

A phase II trial of trastuzumab plus wee

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

✍ Stacy Moulder; Hailun Li; Molin Wang; William J. Gradishar; Edith A. Perez; Jose 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 250 KB